Onabotulinumtoxin A in the treatment of chronic migraine

被引:0
作者
Lainez-Andres, Jose M. [1 ]
机构
[1] Univ Catolica Valencia, Hosp Clin Univ, Serv Neurol, E-46010 Valencia, Spain
关键词
Botulinum toxin type A; Chronic migraine; Episodic migraine; Medication-overuse headache; Onabotulinumtoxin A; TOXIN TYPE-A; CHRONIC DAILY HEADACHE; PLACEBO-CONTROLLED PHASE; QUALITY-OF-LIFE; BOTULINUM-TOXIN; DOUBLE-BLIND; PROPHYLACTIC TREATMENT; EPISODIC MIGRAINE; TOPIRAMATE; MULTICENTER;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Chronic migraine is the most frequent complication of migraine. Its management is complex and difficult, and is based essentially on preventive measures. Aim. To analyse the development of the use of Onabotulinumtoxin A (OnabotA) in migraine, especially in its chronic form, the method of administration, its mechanism of action, its safety profile and its possible indications in clinical practice. Development. The study conducts a thorough review of all the clinical trials in the literature that have used OnabotA in the prevention of migraine, both in its episodic and its chronic forms, and the outcomes in the chronic form are analysed in detail. Conclusions. In studies in phase III, OnabotA has proved to be effective in the treatment of patients with chronic migraine, with significant reductions in the mean frequency of days with headaches, the number of headache episodes, the days with migraine or the proportion of patients with severe disability, in addition to other parameters. It is also effective in the subgroup of patients with symptomatic headache due to medication abuse. OnabotA has proved to be safe and well tolerated in this indication, with foreseeable, usually mild or moderate, transitory side effects. In sum, OnabotA is a safe, well-tolerated alternative in the preventive treatment of chronic migraine.
引用
收藏
页码:S39 / S50
页数:12
相关论文
共 49 条
[1]  
[Anonymous], 2004, CEPHALGIA
[2]   Botulinum toxin: A successful therapeutic protein [J].
Aoki, KR .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (23) :3085-3092
[3]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[4]   Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study [J].
Aurora, Sheena K. ;
Gawel, Marek ;
Brandes, Jan L. ;
Pokta, Suriani ;
VanDenburgh, Amanda M. .
HEADACHE, 2007, 47 (04) :486-499
[5]   OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program [J].
Aurora, Sheena K. ;
Winner, Paul ;
Freeman, Marshall C. ;
Spierings, Egilius L. ;
Heiring, Jessica O. ;
DeGryse, Ronald E. ;
VanDenburgh, Amanda M. ;
Nolan, Marissa E. ;
Turkel, Catherine C. .
HEADACHE, 2011, 51 (09) :1358-1373
[6]  
Bali J., 2005, J. Venom. Anim. Toxins incl. Trop. Dis, V11, P412, DOI 10.1590/S1678-91992005000400003
[7]   Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study [J].
Binder, WJ ;
Brin, MF ;
Blitzer, A ;
Schoenrock, LD ;
Pogoda, JM .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2000, 123 (06) :669-676
[8]   Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program [J].
Blumenfeld, Andrew ;
Silberstein, Stephen D. ;
Dodick, David W. ;
Aurora, Sheena K. ;
Turkel, Catherine C. ;
Binder, William J. .
HEADACHE, 2010, 50 (09) :1406-1418
[9]  
Borrell Wilson María del Carmen, 2006, Rev. Soc. Esp. Dolor, V13, P285
[10]   Migraine prophylaxis with botulinum toxin A is associated with perception of headache [J].
Burstein, Rami ;
Dodick, David ;
Silberstein, Stephen .
TOXICON, 2009, 54 (05) :624-627